Workflow
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Silexion Therapeutics CorpSilexion Therapeutics Corp(US:SLXN) Newsfilter·2024-12-17 11:30

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today revealed its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy. Through this existing collaboration, Evonik's proprietary biodegradable long-acting PLGA (RESOMER®) microparticle ...